Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: An analysis of treatment and survival trends from the National Cancer Database

Journal of Clinical Oncology

Volumn 32, Issue 19, 2014, Pages 2018-2024

  Rueth, Natasha M ^a   Lin, Heather Y ^a   Bedrosian, Isabelle ^a   Shaitelman, Simona F ^a   Ueno, Naoto T ^a   Shen, Yu ^a   Babiera, Gildy ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMMUNITY; FEMALE; HUMAN; INCOME; INFLAMMATORY BREAST CANCER; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PUBLIC HEALTH INSURANCE; RACE; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; HUMANS; INFLAMMATORY BREAST NEOPLASMS; KAPLAN-MEIER ESTIMATE; MASTECTOMY; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84905836920     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.1978     Document Type: Article

References (19)

1. Anderson WF, Schairer C, Chen BE, et al: Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22:9-23, 2005 (Pubitemid 44308938)
2. Hance KW, Anderson WF, Devesa SS, et al: Trends in inflammatory breast carcinoma incidence and survival: The Surveillance, Epidemiology, and End Results program at the National Cancer Institute. J Natl Cancer Inst 97:966-975, 2005 (Pubitemid 41430562)
3. Cristofanilli M, Valero V, Buzdar AU, et al: Inflammatory breast cancer (IBC) and patterns of recurrence: Understanding the biology of a unique disease. Cancer 110:1436-1444, 2007 (Pubitemid 47463056)
4. Dawood S, Ueno NT, Valero V, et al: Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: A large population-based study. Cancer 117:1819-1826, 2011
5. Masuda H, Brewer TM, Liu DD, et al: Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol 25:384-391, 2014
6. National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Program SEER Database: Incidence-SEER Regs Public - Use 2007. www.seer.cancer.gov
7. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, et al: Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: The M. D. Anderson Cancer Center experience. Clin Breast Cancer 4:415-419, 2004 (Pubitemid 38443464)
8. Fleming RY, Asmar L, Buzdar AU, et al: Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol 4:452-461, 1997 (Pubitemid 127725217)
9. Ueno NT, Buzdar AU, Singletary SE, et al: Combined-modality treatment of inflammatory breast carcinoma: Twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol 40:321-329, 1997 (Pubitemid 27276136)
10. Raval MV, Bilimoria KY, Stewart AK, et al: Using the NCDB for cancer care improvement: An introduction to available quality assessment tools. J Surg Oncol 99:488-490, 2009
11. Edge S, Byrd DR, Compton CC, et al (eds): Cancer Staging Handbook from the AJCC Cancer Staging Manual. Chicago, IL, American Joint Committee on Cancer, 2010. www.cancerstaging.org
12. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. www.nccn.org/professionals/physician-gls/f-guidelines.asp
13. Dawood S, Merajver SD, Viens P, et al: International expert panel on inflammatory breast cancer: Consensus statement for standardized diagnosis and treatment. Ann Oncol 22:515-523, 2011
14. Yamauchi H, Woodward WA, Valero V, et al: Inflammatory breast cancer: What we know and what we need to learn. Oncologist 17:891-899, 2012
15. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, et al: Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer 106:1000-1006, 2006
16. Hershman DL, Buono D, McBride RB, et al: Surgeon characteristics and receipt of adjuvant radiotherapy in women with breast cancer. J Natl Cancer Inst 100:199-206, 2008 (Pubitemid 351480552)
17. Pan IW, Smith BD, Shih YC: Factors contributing to underuse of radiation among younger women with breast cancer. J Natl Cancer Inst 106:djt340, 2014
18. Woodward WA, Buchholz TA: The role of locoregional therapy in inflammatory breast cancer. Semin Oncol 35:78-86, 2008 (Pubitemid 351282389)
19. Lerro CC, Robbins AS, Phillips JL, et al: Comparison of cases captured in the national cancer data base with those in population-based central cancer registries. Ann Surg Oncol 20:1759-1765, 2013